Milk Polar Lipids in a High-Fat Diet Can Prevent Body Weight Gain: Modulated Abundance of Gut Bacteria in Relation with Fecal Loss of Specific Fatty Acids.


Journal

Molecular nutrition & food research
ISSN: 1613-4133
Titre abrégé: Mol Nutr Food Res
Pays: Germany
ID NLM: 101231818

Informations de publication

Date de publication:
02 2019
Historique:
received: 08 10 2018
revised: 18 12 2018
pubmed: 11 1 2019
medline: 30 7 2019
entrez: 11 1 2019
Statut: ppublish

Résumé

Enhanced adiposity and metabolic inflammation are major features of obesity associated with altered gut microbiota and intestinal barrier. How these metabolic outcomes can be impacted by milk polar lipids (MPL), naturally containing 25% of sphingomyelin, is investigated in mice fed a mixed high-fat (HF) diet . Male C57Bl/6 mice receive a HF-diet devoid of MPL (21% fat, mainly palm oil, in chow), or supplemented with 1.1% or 1.6% of MPL (HF-MPL1; HF-MPL2) via a total-lipid extract from butterserum concentrate for 8 weeks. HF-MPL2 mice gain less weight versus HF (p < 0.01). Diets do not impact plasma markers of inflammation but in the liver, HF-MPL2 tends to decrease hepatic gene expression of macrophage marker F4/80 versus HF-MPL1 (p = 0.06). Colonic crypt depth is the maximum in HF-MPL2 (p < 0.05). In cecal microbiota, HF-MPL1 increases Bifidobacterium animalis versus HF (p < 0.05). HF-MPL2 decreases Lactobacillus reuteri (p < 0.05), which correlates negatively with the fecal loss of milk sphingomyelin-specific fatty acids (p < 0.05). In mice fed a mixed HF diet, MPL can limit HF-induced body weight gain and modulate gut physiology and the abundance in microbiota of bacteria of metabolic interest. This supports further exploration of how residual unabsorbed lipids reaching the colon can impact HF-induced metabolic disorders.

Identifiants

pubmed: 30628158
doi: 10.1002/mnfr.201801078
doi:

Substances chimiques

Fatty Acids 0
Lipids 0
Sphingomyelins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

e1801078

Informations de copyright

© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Auteurs

Marine Milard (M)

Univ Lyon, CarMeN Laboratory, INSERM U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, 69621, Villeurbanne, France.

Fabienne Laugerette (F)

Univ Lyon, CarMeN Laboratory, INSERM U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, 69621, Villeurbanne, France.

Annie Durand (A)

Univ Lyon, CarMeN Laboratory, INSERM U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, 69621, Villeurbanne, France.

Charline Buisson (C)

Univ Lyon, CarMeN Laboratory, INSERM U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, 69621, Villeurbanne, France.

Emmanuelle Meugnier (E)

Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69600, Oullins, France.

Emmanuelle Loizon (E)

Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69600, Oullins, France.

Corinne Louche-Pelissier (C)

Centre de Recherche en Nutrition Humaine (CRNH) Rhône-Alpes, Centre Européen Pour la Nutrition et la Santé, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, INSERM, Hospices Civils de Lyon, F-69310, Pierre Bénite, France.

Valérie Sauvinet (V)

Centre de Recherche en Nutrition Humaine (CRNH) Rhône-Alpes, Centre Européen Pour la Nutrition et la Santé, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, INSERM, Hospices Civils de Lyon, F-69310, Pierre Bénite, France.

Lorna Garnier (L)

Laboratoire d'Immunologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.

Sébastien Viel (S)

Laboratoire d'Immunologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.

Karène Bertrand (K)

ITERG-ENMS, Université de Bordeaux, Talence, France.

Florent Joffre (F)

ITERG-ENMS, Université de Bordeaux, Talence, France.

David Cheillan (D)

Univ Lyon, CarMeN Laboratory, INSERM U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, 69621, Villeurbanne, France.
Service Biochimie et Biologie Moléculaire Grand Est, Centre de Biologie Est, Hospices Civils de Lyon, Lyon, France.

Lydie Humbert (L)

Sorbonne Universités, UPMC Univ. Paris 06, École normale supérieure, PSL Research University, CNRS, INSERM, APHP, Laboratoire des Biomolécules (LBM), 27 rue de Chaligny, Paris, 75005, France.

Dominique Rainteau (D)

Sorbonne Universités, UPMC Univ. Paris 06, École normale supérieure, PSL Research University, CNRS, INSERM, APHP, Laboratoire des Biomolécules (LBM), 27 rue de Chaligny, Paris, 75005, France.

Pascale Plaisancié (P)

Univ Lyon, CarMeN Laboratory, INSERM U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, 69621, Villeurbanne, France.

Laure B Bindels (LB)

Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Université catholique de Louvain, Brussels, Belgium.

Audrey M Neyrinck (AM)

Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Université catholique de Louvain, Brussels, Belgium.

Nathalie M Delzenne (NM)

Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Université catholique de Louvain, Brussels, Belgium.

Marie-Caroline Michalski (MC)

Univ Lyon, CarMeN Laboratory, INSERM U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, 69621, Villeurbanne, France.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH